BSE Live
Apr 13, 16:01Prev. Close
8291.50
Open Price
8298.25
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 13, 15:47Prev. Close
8299.00
Open Price
8024.50
Bid Price (Qty.)
8725.00 (211)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of AstraZeneca Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 156.36 | 219.54 | 134.10 | 83.04 | 127.09 | |
| Net CashFlow From Operating Activities | 65.36 | 27.87 | 58.29 | 100.80 | 104.78 | |
| Net Cash Used In Investing Activities | 30.80 | 21.74 | 18.11 | 4.74 | 173.03 | |
| Net Cash Used From Financing Activities | -65.59 | -44.38 | -24.48 | -9.46 | -8.97 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 30.57 | 5.23 | 51.92 | 96.08 | 268.84 | |
| Cash And Cash Equivalents Begin of Year | 505.57 | 500.34 | 448.42 | 352.34 | 83.50 | |
| Cash And Cash Equivalents End Of Year | 536.14 | 505.57 | 500.34 | 448.42 | 352.34 |
12.02.2026
01.02.2026
12.11.2025
AstraZeneca Standalone September 2025 Net Sales at Rs 559.09 crore, up 37.03% Y-o-Y
10.11.2025
12.11.2025
AstraZeneca Standalone September 2025 Net Sales at Rs 559.09 crore, up 37.03% Y-o-Y
06.06.2025
AstraZeneca Standalone March 2025 Net Sales at Rs 480.48 crore, up 25.39% Y-o-Y
17.02.2025
AstraZeneca Standalone December 2024 Net Sales at Rs 440.29 crore, up 43.98% Y-o-Y
21.11.2024
AstraZeneca Standalone September 2024 Net Sales at Rs 408.00 crore, up 31.16% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth